Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. Jacob JM, et al. Urol Oncol. 2024 Jan;42(1):20.e17-20.e23. doi: 10.1016/j.urolonc.2023.07.004. Epub 2023 Jul 28. Urol Oncol. 2024. PMID: 37517898
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Woldu SL, Labbate C, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y. Woldu SL, et al. Urol Oncol. 2023 Mar;41(3):147.e15-147.e21. doi: 10.1016/j.urolonc.2022.10.029. Epub 2022 Nov 22. Urol Oncol. 2023. PMID: 36424224
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner B, Feldman A, Lotan Y, Matin SF. Labbate C, et al. J Urol. 2023 May;209(5):872-881. doi: 10.1097/JU.0000000000003185. Epub 2023 Jan 19. J Urol. 2023. PMID: 36657029
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Matin SF, Lotan Y, Feldman AS. Kaimakliotis HZ, et al. Urol Oncol. 2023 Sep;41(9):387.e1-387.e7. doi: 10.1016/j.urolonc.2023.04.010. Epub 2023 May 26. Urol Oncol. 2023. PMID: 37246135
Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)].
Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Linehan J, et al. Eur Urol Focus. 2024 Jan;10(1):211. doi: 10.1016/j.euf.2023.08.006. Epub 2023 Aug 26. Eur Urol Focus. 2024. PMID: 37640582 No abstract available.
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
Taylor JI, Kamat AM, O'Donnell MA, Annapureddy D, Howard J, Tan WS, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguié M, Lerner S, Black PC, Raman JD, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y. Taylor JI, et al. BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509. Online ahead of print. BJU Int. 2024. PMID: 39183466
3,130 results